Nucleonics | GenomeWeb

Nucleonics

Veritas Bio, a biotechnology holding company established by two co-founders of expressed RNAi firm Nucleonics, said this week that the US Patent and Trademark Office has issued a notice of allowance on a patent application covering a novel liver-directed RNAi delivery technology.

With Marina Biotech's back against the wall, the RNAi drugs field may soon see the departure of its third player this year, following the bankruptcy of Traversa Therapeutics and the acquisition of Tacere Therapeutics by Benitec Biopharma.

Although it was one of the earliest patents in the RNAi field, the IP had earlier been deemed invalid by the USPTO after re-examination proceedings were initiated by now-defunct expressed RNAi firm Nucleonics.

Last week, the Australian firm disclosed that the UK Intellectual Property Office has received an application to revoke its UK patent No. 2,353,282, which is related to the '099 patent.

The IP fell under USPTO scrutiny as part of a protracted patent-infringement battle Benitec waged with now-defunct expressed RNAi shop Nucleonics.

The allowed patent covers the use of multiple-promoter expression cassettes for simultaneous delivery of RNAi. Separately, the Aussie shop said the USPTO won’t likely decide a company appeal until the third quarter of next year.

While most companies working in the RNAi drugs field have been able to secure the money needed to maintain operations, a number of players in the space have bowed out under unfavorable circumstances.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.